drugset / Trial / NCT07104110
Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study is designed to determine if experimental treatment with QLH12016 in combination with novel hormonal agent (NHA) is safe, tolerable, and has anti-cancer activity in patients with advanced prostate cancer.
Timeline
- Start
- 2025-10
- Primary completion
- 2027-10
- Completion
- 2028-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QLH12016 | Other / unclassified | — | Oral |
| Background | Abiraterone acetate | Small molecule | — | Oral |
| Background | Enzalutamide | Other / unclassified | — | Oral |